Charles Schwab Investment Management Inc Seres Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $515 Billion
  • Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 748,718 shares of MCRB stock, worth $411,794. This represents 0.0% of its overall portfolio holdings.

Number of Shares
748,718
Previous 525,947 42.36%
Holding current value
$411,794
Previous $378,000 88.1%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$0.7 - $1.48 $155,939 - $329,701
222,771 Added 42.36%
748,718 $711,000
Q2 2024

Aug 12, 2024
SELL
$0.56 - $1.19 $123,967 - $263,431
-221,371 Reduced 29.62%
525,947 $378,000
Q1 2024

May 08, 2024
BUY
$0.75 - $1.56 $53,198 - $110,652
70,931 Added 10.49%
747,318 $575,000
Q4 2023

Feb 06, 2024
SELL
$0.93 - $2.15 $74,567 - $172,387
-80,180 Reduced 10.6%
676,387 $946,000
Q3 2023

Nov 08, 2023
BUY
$2.33 - $5.07 $98,554 - $214,450
42,298 Added 5.92%
756,567 $1.8 Million
Q2 2023

Aug 09, 2023
BUY
$4.67 - $6.55 $375,468 - $526,620
80,400 Added 12.68%
714,269 $3.42 Million
Q1 2023

May 11, 2023
SELL
$4.95 - $6.09 $14,993 - $18,446
-3,029 Reduced 0.48%
633,869 $3.59 Million
Q4 2022

Feb 13, 2023
BUY
$5.09 - $9.05 $70,435 - $125,233
13,838 Added 2.22%
636,898 $3.57 Million
Q3 2022

Nov 14, 2022
BUY
$3.5 - $7.2 $530,852 - $1.09 Million
151,672 Added 32.18%
623,060 $4 Million
Q2 2022

Aug 15, 2022
SELL
$2.7 - $7.62 $29,133 - $82,219
-10,790 Reduced 2.24%
471,388 $1.62 Million
Q1 2022

May 13, 2022
BUY
$6.3 - $8.84 $74,881 - $105,072
11,886 Added 2.53%
482,178 $3.43 Million
Q4 2021

Feb 11, 2022
BUY
$6.02 - $11.43 $26,542 - $50,394
4,409 Added 0.95%
470,292 $3.92 Million
Q3 2021

Nov 16, 2021
BUY
$5.46 - $22.6 $249,620 - $1.03 Million
45,718 Added 10.88%
465,883 $3.24 Million
Q2 2021

Aug 16, 2021
BUY
$18.46 - $24.36 $697,566 - $920,515
37,788 Added 9.88%
420,165 $10 Million
Q1 2021

May 17, 2021
BUY
$17.66 - $28.92 $177,818 - $291,195
10,069 Added 2.7%
382,377 $7.87 Million
Q4 2020

Feb 16, 2021
BUY
$23.25 - $37.73 $688,548 - $1.12 Million
29,615 Added 8.64%
372,308 $9.12 Million
Q3 2020

Nov 13, 2020
SELL
$3.74 - $28.74 $273,749 - $2.1 Million
-73,195 Reduced 17.6%
342,693 $9.7 Million
Q2 2020

Aug 14, 2020
BUY
$3.04 - $6.2 $80,319 - $163,810
26,421 Added 6.78%
415,888 $1.98 Million
Q1 2020

May 15, 2020
BUY
$2.64 - $3.82 $12,033 - $17,411
4,558 Added 1.18%
389,467 $1.39 Million
Q4 2019

Feb 07, 2020
BUY
$2.99 - $4.42 $10,453 - $15,452
3,496 Added 0.92%
384,909 $1.33 Million
Q3 2019

Nov 08, 2019
BUY
$2.29 - $4.16 $235,556 - $427,910
102,863 Added 36.93%
381,413 $1.53 Million
Q2 2019

Aug 09, 2019
BUY
$2.28 - $7.35 $326,156 - $1.05 Million
143,051 Added 105.57%
278,550 $897,000
Q1 2019

May 14, 2019
BUY
$4.83 - $7.21 $67,204 - $100,319
13,914 Added 11.44%
135,499 $931,000
Q4 2018

Feb 14, 2019
SELL
$4.52 - $8.88 $4,104 - $8,063
-908 Reduced 0.74%
121,585 $550,000
Q3 2018

Nov 13, 2018
BUY
$7.33 - $9.23 $38,394 - $48,346
5,238 Added 4.47%
122,493 $930,000
Q2 2018

Aug 08, 2018
BUY
$6.91 - $9.55 $128,263 - $177,267
18,562 Added 18.81%
117,255 $1.01 Million
Q1 2018

May 07, 2018
BUY
$7.34 - $11.16 $23,187 - $35,254
3,159 Added 3.31%
98,693 $725,000
Q4 2017

Jan 17, 2018
SELL
$9.15 - $12.64 $70,930 - $97,985
-7,752 Reduced 7.51%
95,534 $969,000
Q3 2017

Nov 13, 2017
BUY
$12.81 - $16.85 $1.32 Million - $1.74 Million
103,286
103,286 $1.66 Million

Others Institutions Holding MCRB

# of Institutions
82
Shares Held
40.5M
Call Options Held
304K
Put Options Held
471K
View Full List

About Seres Therapeutics, Inc.

MCRB Quotes by TradingView
  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $68.2M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email